Perspectives on the mesenchymal origin of metastatic cancer.
Level 5 - mechanism / opinion, no new human data
Narrative review presenting theoretical mechanism-based reasoning without original human data or systematic review methodology.
PubMed 20839033 · doi:10.1007/s10555-010-9254-z
What was done
This is a narrative review synthesizing conceptual and biological evidence regarding the cellular origins of metastatic cancer. The authors evaluate literature on human cancers exhibiting macrophage-like properties—including phagocytosis, fusogenicity, and specific gene/protein expression patterns—and compare a myeloid/macrophage origin hypothesis against traditional clonal evolution and epithelial-mesenchymal transition frameworks.
What was found
The abstract reports no numerical data, effect sizes, or study counts. It presents the theoretical conclusion that metastatic cancer cells likely arise from damaged pre-existing mesenchymal/macrophage-type cells already equipped with metastatic behavioral capacities, rather than from random somatic mutations in epithelial cells.
Why it matters
Reframing metastasis as a myeloid-lineage disease challenges dominant epithelial-mesenchymal transition paradigms and could alter biological targets for anti-metastatic drug development.
Limits
This is a non-systematic narrative perspective containing no original empirical human data, quantitative meta-analysis, or lineage-tracing validation. The abstract lacks measurable outcomes, sample sizes, and comparative statistical testing.
Cited by
- partial All metastatic cancer cells exhibit characteristics of macrophages and depend on glucose and glutamine for survival.